CFO interim
Jasper Therapeutics, Inc. names Jeet Mahal interim CFO
Jasper Therapeutics, Inc. reported in a Form 8-K filed September 28, 2026 that Jeet Mahal was named interim interim Principal Financial Officer, effective October 9, 2026.
In the filing's words
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the “ Company ”) in order to pursue other professional endeavors.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Jasper Therapeutics, Inc. (JSPR) |
|---|---|
| Event | Interim |
| Incoming | Jeet Mahal |
| Outgoing | Herb Cross |
| Title in the filing | interim Principal Financial Officer |
| Effective | October 9, 2026 |
| 8-K filed | September 28, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | President and Chief Executive Officer, Jasper Therapeutics, Inc. |
| SEC CIK | 0001788028 |
Jasper Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 28, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-29
Something wrong about Jeet Mahal? Send a correction with the primary source.